Moreover, Wang Ruonan’s team designed a DC-targeting nanoregulator (DNR) that reprograms dendritic cells in tumor-draining lymph nodes (TDLNs) by synergistically activating TLR4 (via mannan) and TLR7/8 (via an IMDQ prodrug) signaling pathways. Here, TLR4 is linked to neoplasm.